Equities research analysts expect The Cooper Companies, Inc. (NYSE:COO) to announce $747.76 million in sales for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Cooper Companies’ earnings, with the highest sales estimate coming in at $749.90 million and the lowest estimate coming in at $745.50 million. Cooper Companies posted sales of $681.60 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 9.7%. The company is scheduled to report its next earnings report after the market closes on Thursday, December 2nd.
According to Zacks, analysts expect that Cooper Companies will report full year sales of $2.91 billion for the current financial year, with estimates ranging from $2.90 billion to $2.91 billion. For the next fiscal year, analysts expect that the company will report sales of $3.09 billion, with estimates ranging from $3.05 billion to $3.11 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that follow Cooper Companies.
Cooper Companies (NYSE:COO) last released its quarterly earnings results on Wednesday, September 1st. The medical device company reported $3.41 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.29 by $0.12. The firm had revenue of $763.40 million during the quarter, compared to the consensus estimate of $727.30 million. Cooper Companies had a net margin of 102.48% and a return on equity of 11.42%. The company’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.28 earnings per share.
Shares of COO stock traded down $7.60 during trading hours on Friday, hitting $390.84. 327,117 shares of the company’s stock traded hands, compared to its average volume of 266,070. The stock’s 50 day simple moving average is $416.45 and its 200 day simple moving average is $412.32. The stock has a market cap of $19.27 billion, a PE ratio of 6.66, a price-to-earnings-growth ratio of 2.52 and a beta of 0.83. Cooper Companies has a 12 month low of $324.34 and a 12 month high of $463.59. The company has a quick ratio of 0.83, a current ratio of 1.39 and a debt-to-equity ratio of 0.17.
In other Cooper Companies news, CFO Brian G. Andrews sold 4,963 shares of the stock in a transaction on Tuesday, September 7th. The stock was sold at an average price of $453.12, for a total transaction of $2,248,834.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Daniel G. Mcbride sold 72,624 shares of the firm’s stock in a transaction on Tuesday, September 7th. The stock was sold at an average price of $450.13, for a total value of $32,690,241.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 79,387 shares of company stock valued at $35,732,390. 1.70% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of the stock. Amundi purchased a new position in shares of Cooper Companies during the 2nd quarter valued at about $234,819,000. Macquarie Group Ltd. boosted its stake in Cooper Companies by 27,074.6% in the second quarter. Macquarie Group Ltd. now owns 444,304 shares of the medical device company’s stock worth $176,063,000 after buying an additional 442,669 shares in the last quarter. Invesco Ltd. boosted its stake in Cooper Companies by 35.7% in the third quarter. Invesco Ltd. now owns 1,585,683 shares of the medical device company’s stock worth $655,378,000 after buying an additional 417,077 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Cooper Companies by 53.4% in the third quarter. Bank of New York Mellon Corp now owns 828,234 shares of the medical device company’s stock worth $342,318,000 after buying an additional 288,394 shares in the last quarter. Finally, Findlay Park Partners LLP boosted its stake in Cooper Companies by 87.2% in the second quarter. Findlay Park Partners LLP now owns 567,709 shares of the medical device company’s stock worth $224,966,000 after buying an additional 264,455 shares in the last quarter. Institutional investors own 96.89% of the company’s stock.
Cooper Companies Company Profile
The Cooper Cos, Inc operates as a medical device company. It operates through the Cooper Vision and Cooper Surgical segments. The Cooper Vision segment develops, manufactures, and markets products for contact lens wearers, which solves vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues.
Read More: What is the G-20?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.